Cadila Healthcare rose 2.22% to Rs 415.85 after the company said it has started supplying its COVID-19 vaccine, ZyCoV-D, to the Government of India.
The drug maker said it is also planning to make the vaccine available in the private market.ZyCoV-D is a three dose Plasmid DNA vaccine administered intradermally using the painless PharmaJet needle free system, Tropis, on day 0, day 28 and day 56. The vaccine which when administered produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which play a vital role in protection from disease as well as viral clearance.
The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs 93 per dose excluding GST.
The company's newly commissioned Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Ahmedabad, Gujarat manufactures the drug substance for ZyCoV-D.
Zydus has also entered into a definitive agreement with Shilpa Medicare, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit surged 608.10% to Rs 2,999.60 crore on 2.4% increase in net sales to Rs 3,687 crore in Q2 FY22 over Q2 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU